Vicuron's Dalbavancin User Fee Date Extended To Sept. 21

FDA extends user fee deadline for the lipoglycopeptide antibiotic by three months to review additional chemistry, manufacturing & controls data. Vicuron plans to amend the NDA for its antifungal anidulafungin in the second quarter.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet